AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2692-9406/065
1 Cliniques Universitaires de Kinshasa,D R Congo.
2 Secrétariat Technique COVID-19, INRB, Kinshasa, D R Congo.
*Corresponding Author: Jean-Marie N. Kayembe, Cliniques Universitaires de Kinshasa, Secrétariat Technique COVID-19, INRB, Kinshasa, D R Congo.
Citation: Kayembe JMN, D Ishoso, C Mbongopasi, Don J Mavungu, Jean R Makulo. (2021) Our experience of using Hydroxychloroquine and Azithromycin in the treatment of COVID-19: an observational study from Kinshasa, Democratic Republic of Congo. Biomedical Research and Clinical Reviews. 4(1); DOI: 10.31579/2692-9406/065
Copyright: © 2021 Jean-Marie N. Kayembe, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 22 April 2021 | Accepted: 04 May 2021 | Published: 07 May 2021
Keywords: hydroxychloroquine; azithromycin; conventional treatment; COVID-19; Kinshasa; Democratic Republic of Congo
Background: Up to now COVID-19 treatment is a matter of great debate. Several trials and observational studies have brought conflicting results regarding the efficacy of some repurposed drugs suggested treating COVID-19, stressing the need for further research.
Objective: This study aimed to add to the existing literature, some evidence on the efficacy and safety of hydroxychloroquine (HCQ) and azithromycin (AZ) as suggested drugs for COVID-19 treatment.
Materials and Methods: This observational study reports the experience of conventional treatment (CT) combining HCQ plus AZ applied in the Democratic Republic of Congo. We compared epidemiological and clinical data between 1,100 (89%) subjects submitted to the CT and 135 (11%) who did not receive the CT. Survival analyses including Kaplan-Meier and Cox regression were used to determine the clinical progress at day 10 and the survival likelihood at day 15, from the treatment initiation date.
Results: Clinical outcome is much better in the CT group on D10 than in the comparison group (p=0.001). The adverse effects reported are minor and equivalent in both groups (3% vs 3%).
Conclusion: This preliminary observational study suggests a beneficial and safe effect of conventional treatment in our country and justifies the continuation of this therapeutic protocol at this time. However, larger analytical studies with more robust evaluation criteria are needed to strengthen the power of observations.
Since the first cases of COVID-19 were reported in Wuhan, China, in December 2019, the medical world has faced an unprecedented challenge. Numerous clinical trials of effective drugs against SARS-CoV-2, a well-identified etiological agent, are regularly published. But despite all these efforts, there is currently no consensual drug optimally effective. Efficacy criteria must incorporate anti-viral and/or immunomodulatory properties of drug candidates currently recommended in clinical trials, and often prescribed compassionately [1].
While randomized clinical studies allow for a better determination of cause-effect relationships between an intervention and outcome, they are not easy to conduct in the face of this pandemic in which the physiopathogenic knowledge of CoV-2 SARS is far from being definitively well known. Researchers undertake observational clinical studies with sometimes questionable power.
They are harnessing knowledge about molecules that have been used for decades in other diseases or against other viruses. Chloroquine belongs to this group of pharmacological agents, known for its anti-viral and immunomodulatory properties [2-5]. With its less toxic derivative, hydroxychloroquine, this drug has been used since the 1950s in the treatment of malaria [6, 7], but also in the management of certain inflammatory and autoimmune conditions such as disseminated Lupus erythematosus [8]. Its antiviral properties, demonstrated in vitro, have led many research teams to propose it as a COVID-19 treatment [9, 10].
Previous studies have shown that hydroxychloroquine prevents the virus from entering host cells in two ways. The first, by inhibiting the receptor of the angiotensin conversion enzyme 2 (ACE2). Indeed, the binding of the viral spike protein (S) to the ACE2 receptor is sufficient for serine transmembrane protease (TMPSS2) to induce the cleavage of the S protein in S1 and S2, thus exposing the FP fusion peptide. It is through FP that the membrane of the virus merges with the host cell. This allows the release of viral particles into the cell [7-10].
The other pathway is accomplished, by increasing the pH (by the input of protons) in the endosomes, reducing the action of the cathepsin-L and inhibiting the fusion of the viral membrane and endosomes [7-10]. It is possible that other proteases, not influenced by hydroxychloroquine, are also involved in the activation of the viral protein S. However, the drug may also inhibit the release of pro-inflammatory cytokines (7, 11). This molecule has been proposed by many teams in pre- or post-exposure prophylaxis, or as a treatment in benign and early-stage forms of COVID-19[10-13]. The conclusions of these clinical trials are contradictory. Positive results on symptom reduction, in-hospital time but not mortality have been described in some previous studies [14, 15].
Since the first case of COVID-19 reported in Kinshasa, on 10th of March 2020, the Technical Secretariat in charge of the response proposed a monitoring strategy around diagnosis, isolation of all RT-PCR positive cases, and their treatment by the combination of hydroxychloroquine (HCQ)/chloroquine (CQ) - Azithromycin (AZ) - Vitamin C with or without zinc, presented as the conventional treatment. This choice was based on the known antiviral effect of these drugs in vitro and data reported, notably by the IHU of Marseille in France, on the reduction of viral load by 100% on D7 by this association, as well as on its beneficial clinical outcomes [5].
On the other hand, chloroquine had been extensively used in the treatment of malaria in our country, with an assured safety profile, and is easily accessible, despite the weakness of our health system. Its early use in COVID 19 would have beneficial effects as reported in some clinical trials worldwide [16, 17], in contrast to the negative results reported mainly in clinical trials in North America [18]; however, there is no established evidence of positive action on severe cases and on mortality. The conflicting results of studies on the effectiveness of hydroxychloroquine against COVID-19 have prompted the DRC to choose to consider as much as possible locally generated data as evidence in therapeutic choices.
Current data on the physiopathogenic mechanisms of SARS-COV-2 in COVID-19 have led to a better definition of therapeutic targets for this condition, which may involve multiple organs. The interest in using molecules with anti-inflammatory properties is justified given the existence of a higher inflammatory phase in the disease; substances modulating the production of cytokines are useful for countering the cytokines storm [19, 20] and anticoagulants have their indication in this pathology in which exaltation of pro-thrombotic mechanisms has been described [21].
This retrospective study reports observations on analyses of COVID-19 in the hospital. It aims to determine the potential effect of CT on clinical outcomes and survival rate, as well as main adverse events found.
We conducted a cohort analysis using routinely collected data from the DRC Ministry of Health’s COVID-19 Multi-Sectoral Response Committee database, spanning March 10, 2020–August 31, 2020. All COVID-19 patients admitted at the ten largest health facilities in Kinshasa were eligible for inclusion. Patients were staged according to the current COVID-19 clinical categories in use elsewhere of mild, moderate, severe, and critical disease. Patients were followed and/or hospitalized at 10 treatment centers in the city of Kinshasa, including: Saint Joseph Hospital (n=152), Cinquantenaire Hospital (n=100), HJ Hospital (n=52), Sino-Congolais Hospital (n=99), Kinshasa University Hospital (n=270), Kinshasa Medical Center (n=18), Ngaliema Clinic (n=347), Diamant Clinic (n=34), Vijana Medical Center (n=189), Monkole Medical Center (n=102). The data were collected using an Excel spreadsheet; and analyzed using STATA15 software (StataCorp.2017. Stata Statistical Software: Release 15.College Station, TX: StataCorp LLC)
Treatment and control groups were formed. With 135 patients in the control group out of 1, 235 patients. This second group included patients enrolled before the availability of Chloroquine and those with formal contraindications, including heart conditions such as arrhythmia or elongation of QT interval. Indeed, cardiac toxicity of HCQ has been reported in previous studies [8, 22]. They were mostly on Artemether/Lumefantrine associated with either Azithromycin or amoxicillin/clavulanic acid.
Sociodemographic, clinical, and paraclinical characteristics were recorded and then compared between the two groups. The proportion for categorical variables, and medians for quantitative as non-symmetrical were used. Statistical tests including the Kruskal-Wallis, Pearson Chi2, Fisher exact, were used as appropriate. The subjects were matched using the nearest neighbor method, and the effects of the treatment were adjusted to the propensity score. The threshold α - 0.05 has been set to establish the significance of differences observed.
Of the hospitalized patients, 988 were followed up to D15 (arbitrarily determined) to assess their likelihood of survival. The Kaplan-Meier method was used for this purpose and the curves were compared using the Log-rank test. A Cox model was then established, based on an automatic selection of FORWARD-type variables based on the probability ratio (LR), using an entry probability of 0.05. The measures of association between each independent variable and survival were reported in the form of a Hazard Ratio accompanied by their 95% confidence intervals. The final model took up only the variables with significant effects after adjustment. Regression was achieved when the verification of the proportionality of hazards was conclusive by a non-significant global test and horizontal-trend Schoenfeld residues, as well as in the presence of parallel in-in curves of predictors over time. The safety of use of conventional treatment was compared to other treatments and evaluated by recording all adverse events (AI) reported by patients and encoded. These were categorized according to version 23.0 of the Medical Dictionary for Regulatory Authorities (MedDRA) and the following parameters were assessed for each AI: severity, duration, time of appearance, actions taken and outcome.
A1. Effects of conventional treatment
Of the 1,235 files selected, 1,100 (89%) were treated by the CT, and 135 (11%) were assigned to the control group.
Table 1 compares some socio-demographic characteristics and does not reveal any significant difference between the groups.
Table 2 compares some clinical and paraclinical characteristics in both groups, as well as the frequency of comorbidities and the clinical stage at admission.
With no number of subjects; No number of subjects in the modalities; fisher's exact test.
Except for the clinical stage at admission, the distribution of comorbidities and other clinical and paraclinical data included in this table is not significantly different between the two groups.
The histograms illustrating the distribution of patient propensity scores in Figure 1 shows, in the CT group, a score ranging from 6.5 to 1 and in the second group from 5 to nearly 1. Matching is therefore visually possible with a very large majority of subjects.
After adjusting the propensity score (matching according to sociodemographic characteristics, comorbidities and clinical stages at admission), table 3 shows a significantly positive outcome in asymptomatic patients on the 10th day of treatment.
After adjusting for the propensity score (matching according to sociodemographic characteristics, comorbidities, and clinical stages at admission), table 4 shows that lethality is significantly lower in the presence of CT.
Table 5a: Adverse events
Table 5a reveals that there is no significant difference in the occurrence of adverse events in both groups.
After adjustment (table 6), patient survival is significantly associated with treatment administered, age group, obesity, and clinical stage at admission.
Moreover, the instantaneous risk of death is significantly high in patients who have not received conventional treatment, aged 50 and over, obese, and at critical, severe and moderate clinical stages.
The current clinical observation shows essentially a beneficial effect on clinical symptoms and lethality at D10 in COVID-19 patients admitted in the 10 treatment centers at Kinshasa. Main predictors of lethality identified were: age over 50 years and comorbidities including obesity, HTA and diabetes mellitus. Conventional treatment was linked to a positive outcome at D15 in the study group; and no harmful adverse events were recorded in the two groups.
Despite the comparison with a group containing far fewer subjects who did not receive conventional treatment (1,100 subjects vs 135), the use of propensity score allowed to minimize the disparities due to the sample size (Figure 3).
The predominance of male gender among positive subjects for SARS CoV-2 observed in this study is in line with demographic data previously reported by other authors [23-25], and even in a recent study from our country [26]. This gender predominance does not find any obvious explanations at this time. It may be dependent on the protection afforded by the X chromosome and the sex hormones that could influence innate and adaptive immunity, as reported previously by Long-Quan Li et al [25], and also by Jaillon et al [27]. These authors have suggested the impact of sexual dimorphism on the different susceptibility to infections or autoimmune diseases according to the gender.
The negative impact of comorbidities, including obesity, HTA and diabetes mellitus, on the global mortality is widely reported. It may reflect the prevalence of these pathologies worldwide; with a trend towards male predominance according to WHO declaration [28]. According to the age, our study has found more subjects under the age of 50 years in disagreement with observation from developed countries, where the COVID-19 seems to affect older people [29, 30]. This could be explained by lower life expectancy in developing countries compared to developed countries in Europe, North America, or Asia.
HTA was the main comorbidity in both groups, along with diabetes mellitus and obesity, as in most previous publications [30, 31].
Symptom improvement at D10 was better in patient under conventional treatment (86% vs 63%); mainly in early administration as observed in an analysis of 126 studies published in October 2020, showing a significantly positive effect on mortality rate, length of hospitalization, and symptom amendment in COVID-19 patient [18].
The positive effect of HCQ was also described by a Chinese team, in a randomized study conducted in Wuhan, China, reporting faster clinical improvement and that of thoracic scannographic images on D6, in 31 out of 62 patients under 400 mg of hydroxychloroquine per day for 5 days [32]. In a systematic review of the literature, Sarma et al showed significant efficacy of HCQ alone or in association on clinical and virological healing, as well as on death or deleterious course of the disease [16].
The predictors of lethality identified in this work were age, clinical stage at admission, and presence of comorbidities. These factors are widely recognized by many authors at present.
Looking at the possible effect of CT on lethality, the current study reveals its slight benefit comparing the two groups. The effects of hydrocholoroquine alone or associated with azithromycin on mortality are far from consensual. However, this observation is consistent with the results presented by Arshad et al in a multicenter retrospective survey conducted in Michigan (USA). These authors described an improvement in survival when hydroxychloroquine, azithromycin, or combination were administered within 2 days of hospitalization [33].
Our study is also enhanced by data from Marseille in France, showing a lower mortality rate among 1,061 patients receiving equivalent doses of the combination HCQ- AZT, as in our CT [30]. In the same trend, Ladapo et al conducted a meta-analysis of randomized studies to determine the preventive effect of early and outpatient HCQ treatment on new infections, hospitalization, and death. These authors concluded that the drug had a positive effect on all three outcomes and reported minor adverse events, especially gastrointestinal disorders [34].
However, our results are in disagreement with those from two New York teams, reporting no benefit on clinical outcome and mortality reduction with the same combination therapy (35). The same observation has been described by Geleris et al, showing neither clinical improvement, nor reduction in mortality rate among 1,376 moderate and severe COVID-19 patients in the same state [36].
These disparities could be explained by the difference in the severity of disease and associated comorbidities at hospital admission, the therapeutic protocol applied, the delay in hospital reference, the available equipment and staff expertise. Early treatment is a determining factor in the prognosis of patients treated for COVID-19. Early outpatient administration of HCQ-AZ to symptomatic COVID-19 patients at high risk of hospitalization and rapid worsening has been shown to be beneficial [37].
Unlike the major side effects, especially cardiac ones, described by some authors [36, 37], this study found only minor manifestations, including pruritus and gastrointestinal disorders. Our data are in agreement with other studies, using the same protocols at almost the same drug doses. These results argue for the safety of hydroxychloroquine in this indication, imposing nevertheless an electrocardiographic control beforehand, as well as a monitoring of possible electrolytic disorders.
Few limitations need to be considered in the interpretation of the results presented.
The impact of adjuvant interventions, including oxygen therapy in both groups has not been formally investigated. Recording data in treatment centers that do not have an equivalent level of expertise may have influenced the future of patients. These limitations could have affected the validity of the results of this study, showing the safety of the national protocol in use in our country, as opposed to the major adverse effects described mainly in Western publications.
These encouraging effects on clinical and safety parameters, as reported elsewhere in Sub-Saharan Africa, justify the continuation of this therapeutic protocol at this time.
This study aimed to add to the existing literature, some evidence on the efficacy and safety of hydroxychloroquine and azithromycin as suggested drugs for COVID-19. The results of this observational clinical study show a beneficial effect of hydroxychloroquine-azithromycin combination on symptoms and lethality in COVD-19 patients. We report the absence of major adverse events that reinforces its widespread use in the global community. The effects of hydroxychloroquine-azythromycin combination on clinical and safety parameters support the continuation of this therapeutic protocol. However, future clinical trials are required to support these findings.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
